Kyle Tokarz, DO
Pain Medicine · Dartmouth, MANPI 1649242637
Payments from drug & device makers
Across 44 payments — averaging $23.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$415
- Abbott$117
- Teva Pharmaceuticals USA, Inc.$92
- Nevro Corp.$81
- UCB, Inc.$64
- Pfizer$47
- plus $218 from 9 others
What the payments were for
- Food & beverage$1,035100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 17 | $415 |
| Abbott | 4 | $117 |
| Teva Pharmaceuticals USA, Inc. | 5 | $92 |
| Nevro Corp. | 4 | $81 |
| UCB, Inc. | 2 | $64 |
| Pfizer | 2 | $47 |
| Stimwave Technologies Incorporated | 2 | $40 |
| Johnson & Johnson | 1 | $34 |
| CSL Behring | 1 | $30 |
| Argenx US, Inc. | 1 | $24 |
| Stryker | 1 | $24 |
| Tonix Medicines, Inc. | 1 | $19 |
| Bioventus LLC | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| AstraZeneca | 1 | $15 |
How this compares
$1,035 in reported general payments places this provider in the 40th percentile of 137 pain medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 148 | $80,459 |
| Xtampza ErOxycodone Myristate | 48 | $35,299 |
| NucyntaTapentadol Hcl | 29 | $24,575 |
| Buprenorphine | 68 | $17,222 |
| Nucynta ErTapentadol Hcl | 14 | $16,570 |
| BelbucaBuprenorphine Hcl | 23 | $14,460 |
| Gabapentin | 778 | $13,920 |
| Lidocaine | 116 | $10,704 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 351 | $8,205 |
| MovantikNaloxegol Oxalate | 17 | $6,797 |
| Duloxetine Hcl | 391 | $6,755 |
| Oxycodone Hcl | 362 | $6,513 |
| Celecoxib | 316 | $6,193 |
| Fentanyl | 76 | $6,100 |
| Baclofen | 301 | $5,965 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Dartmouth
- Jeffrey NortonLawrence$44.4M
- Christine SangBoston$2.5M
- Hariharan SundramNewton$1.7M
- Pradeep DinakarBoston$227K
- Jatinder GillBoston$190K
- Thomas SimopoulosBoston$181K
- Arti OriBoston$105K
- Ivan UritsWareham$70K
- Antje BarreveldNewton$64K
- Ali EbrahimiBurlington$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.